Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 253 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Itching Clear all
Completed Phase 3 Interventional Results available

A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines

NCT05030311
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
LOU064 25 mg (b.i.d), Placebo, LOU064 25 mg (b.i.d) as a tablet.
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
26
States / cities
Birmingham, Alabama • North Little Rock, Arkansas • Bakersfield, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 22, 2026, 4:03 AM EDT
Completed Phase 2 Interventional Results available

Study of TS-022 in Adult Patients With Atopic Dermatitis With Pruritus (POC)

NCT00914186
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
TS022, Vehicle
Drug
Lead sponsor
Taisho Pharmaceutical R&D Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
15
States / cities
La Jolla, California • San Diego, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2011 · Synced Oct 22, 2026, 4:03 AM EDT
Completed Phase 2 Interventional Results available

Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary Cholangitis

NCT02966834
View directory record Official record
Conditions
Cholestasis
Interventions
Placebo, GSK2330672
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
9
States / cities
Phoenix, Arizona • Sacramento, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 22, 2026, 4:03 AM EDT
Completed Phase 3 Interventional

A Clinical Trial to Evaluate the Safety and Efficacy of Enjuvia 0.3 mg for the Treatment of Vulvovaginal Atrophy

NCT00196378
View directory record Official record
Conditions
Menopause
Interventions
Synthetic Conjugated estrogens, B, Placebo
Drug · Other
Lead sponsor
Duramed Research
Industry
Eligibility
30 Years to 80 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
38
States / cities
Huntsville, Alabama • Tucson, Arizona • Carmichael, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2013 · Synced Oct 22, 2026, 4:03 AM EDT
Completed Phase 3 Interventional Results available

CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

NCT03998163
View directory record Official record
Conditions
Uremic Pruritus
Interventions
CR845 0.5 mcg/kg
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
33
States / cities
Escondido, California • Riverside, California • San Diego, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 22, 2026, 4:03 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis

NCT03011892
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib 0.15% Cream QD, Ruxolitinib 0.5% Cream QD, Ruxolitinib 1.5% Cream QD, Ruxolitinib 1.5% Cream BID, Triamcinolone 0.1% Cream BID, Vehicle Cream BID
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
35
States / cities
Birmingham, Alabama • Bryant, Arkansas • Encino, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2021 · Synced Oct 22, 2026, 4:03 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)

NCT06516952
View directory record Official record
Conditions
Prurigo Nodularis
Interventions
Povorcitinib, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
31
States / cities
Birmingham, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 26 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 22, 2026, 4:03 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

NCT06979453
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Deucravacitinib, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years to 17 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 22, 2026, 4:03 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis

NCT03517566
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Placebo, ZPL389 3mg, ZPL389 10mg, ZPL389 30mg, ZPL389 50mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
12
States / cities
Litchfield Park, Arizona • Fountain Valley, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2021 · Synced Oct 22, 2026, 4:03 AM EDT
Completed Phase 2 Interventional

A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis

NCT03897257
View directory record Official record
Conditions
Tinea Pedis
Interventions
UHE-103A1 cream, UHE-103A2 cream, UHE-103B cream, UHE-103A1B cream, UHE-103A2B cream
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
16 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
11
States / cities
San Diego, California • Melbourne, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 22, 2026, 4:03 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)

NCT07811869
View directory record Official record
Conditions
Chronic Pruritus of Unknown Origin
Interventions
Remibrutinib, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Tampa, Florida • Brighton, Massachusetts • Clarkston, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 22, 2026, 4:03 AM EDT
Completed Not applicable Interventional Results available

Effects of Transcranial Direct Current Stimulation (tDCS) on Neuropathic Symptoms Following Burn Injury

NCT01795079
View directory record Official record
Conditions
Burn Injury, Chronic Pain, Pruritus, Itching
Interventions
Transcranial direct current stimulation (tDCS)
Device
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Oct 22, 2026, 4:03 AM EDT
Recruiting Phase 4 Interventional

Obtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis Patients Using Topical Roflumilast Cream.

NCT07560618
View directory record Official record
Conditions
ITCH, Atopic Dermatitis
Interventions
Roflumilast Cream 0.15%
Drug
Lead sponsor
Integrative Skin Science and Research
Industry
Eligibility
12 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 22, 2026, 4:03 AM EDT
Terminated Phase 3 Interventional

CR845-310302: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

NCT05356403
View directory record Official record
Conditions
Chronic Kidney Diseases, Pruritus
Interventions
Difelikefalin 1 mg Oral Tablet, Placebo Oral Tablet
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
9
States / cities
Northridge, California • Miami, Florida • Miami Lakes, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 22, 2026, 4:03 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Assessment of Suppression of Cutaneous Allergic Responses and Pruritus by Topical Doxycycline

NCT03968562
View directory record Official record
Conditions
Hives
Interventions
2% Doxycycline Cream in Generic Aquaphor or Generic Aquaphor
Drug
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 22, 2026, 4:03 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

NCT04501666
View directory record Official record
Conditions
Prurigo Nodularis
Interventions
Nemolizumab 30 mg, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
38
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 22, 2026, 4:03 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Tinea Pedis

NCT05493488
View directory record Official record
Conditions
Tinea Pedis
Interventions
DBI-001 Gel, DBI-002 Gel, Aqueous Gel
Biological
Lead sponsor
DermBiont, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Portland, Oregon • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Oct 22, 2026, 4:03 AM EDT
Not listed Not applicable Interventional

Hypnosis for Pain and Itch Following Burn Injuries

NCT01828541
View directory record Official record
Conditions
Burns
Interventions
Hypnosis, Standard of Care
Behavioral · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 12, 2017 · Synced Oct 22, 2026, 4:03 AM EDT
Completed Phase 2 Interventional Results available

Tofacitinib Ointment For Chronic Plaque Psoriasis

NCT01831466
View directory record Official record
Conditions
Psoriasis Vulgaris, Psoriasis
Interventions
tofacitinib ointment 20 mg/g, tofacitinib ointment 10 mg/g, placebo ointment (vehicle)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
476 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
29
States / cities
Hot Springs, Arkansas • Bakersfield, California • Irvine, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Oct 22, 2026, 4:03 AM EDT
Completed Phase 2 Interventional Results available

B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis

NCT04490109
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus
Interventions
B244, Vehicle
Biological
Lead sponsor
AOBiome LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
56
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 22, 2026, 4:03 AM EDT
Completed No phase listed Observational

Study of Kids Itch Severity (SKIS)

NCT02672579
View directory record Official record
Conditions
Chronic Pruritus
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
4 Years to 17 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 22, 2026, 4:03 AM EDT
Terminated Phase 4 Interventional Results available

Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis

NCT05200403
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole 2%, Vehicle treatment, Accelerometry device for children, Accelerometry device for adult caregivers
Drug · Device
Lead sponsor
Boston University
Other
Eligibility
3 Months to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 22, 2026, 4:03 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

NCT02858726
View directory record Official record
Conditions
Uremic Pruritus
Interventions
CR845 0.5 mcg/kg, CR845 1 mcg/kg, CR845 1.5mcg/kg, Placebo
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
29
States / cities
Phoenix, Arizona • Pine Bluff, Arkansas • Long Beach, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2020 · Synced Oct 22, 2026, 4:03 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Equivalence of Estradiol Vaginal Cream to Reference Standard in the Treatment of Vaginal Atrophy

NCT03332303
View directory record Official record
Conditions
Vulvar and Vaginal Atrophy
Interventions
Estrace® Cream, Estradiol Vaginal Cream, Vehicle Cream
Drug
Lead sponsor
Prasco LLC
Industry
Eligibility
30 Years to 75 Years · Female only
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
27
States / cities
Sacramento, California • San Diego, California • Denver, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Oct 22, 2026, 4:03 AM EDT